New antibiotic drugs are urgently required to combat antibiotic-resistant pathogenic bacterial infections. The identification of a drug candidate that is both effective and safe is a critical part of the pre-clinical drug discovery and development process. It is an ever-present and high-cost hurdle in the process for both research institutions and pharmaceutical companies. Ynno Med Limited proposes to offer products as antimicrobial drug candidate pipelines targeting large companies. We aim to develop validated drug candidates with self-owned IP as products. Our products will provide target-focused and rationally designed potential drug candidates to large pharmaceutical companies seeking “first-in-class” new drug candidates.